Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib and dexamethasone (PVd) significantly improved the progression‐free survival (PFS) and the overall response rate (ORR) vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma. All patients were previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunami, Kazutaka, Matsue, Kosei, Suzuki, Kenshi, Takezako, Naoki, Shinagawa, Atsushi, Sakurai, Sanae, Tamakoshi, Hiromi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293071/
https://www.ncbi.nlm.nih.gov/pubmed/32297407
http://dx.doi.org/10.1111/cas.14415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293071/
https://www.ncbi.nlm.nih.gov/pubmed/32297407
http://dx.doi.org/10.1111/cas.14415

Ejemplares similares